王瑞;郭亭;曾晓峰;周利武;董磊;张峻峰;赵建宁;

• 1:南京军区南京总医院第二军医大学南京临床学院骨科
• 2:南京大学生物医药重点实验室

摘要(Abstract)：

[目的]研究单次皮下注射靶向肿瘤坏死因子α(tumor necrosis factor,TNF-α)的反义寡核苷酸(antisense oligonucleotides,ASO)治疗人工关节磨损微粒诱导的骨溶解的作用,探讨用于防治人工关节置换后假体松动的可能性。[方法]采用小鼠颅骨建立微粒诱导的骨溶解的动物模型,分为5组:第1组为假手术组,第2组为阳性对照组,第3组为低剂量治疗组,第4组为高剂量治疗组,第5组在第四组处置的基础上再次给予TNF-α。通过甲苯胺蓝染色观察颅骨表面骨吸收陷窝的数量并测量其面积,通过抗酒石酸的酸性磷酸酶(tartrate-resistant acid phospha-tase,TRAP)染色来观察破骨细胞并进行计数,通过定量试剂盒对TRAP的活性进行定量研究。同时采用RT-PCR和ELISA的方法检测TNF-α的表达。[结果]靶向TNF-α的ASO可以显著下调靶基因的表达,对微粒诱导的骨溶解有明显的抑制作用。骨吸收陷窝的数目与面积以及破骨细胞的数量均较阳性对照组有明显下降,定量研究显示TRAP的活性也有明显的下降。这种改变与ASO的用量呈明显的依赖性,高剂量组的治疗结果接近于假手术组。再次给予TNF-α可以逆转这种抑制效果。[结论]靶向炎症因子TNF-α的反义核酸通过抑制TNF-α表达,抑制了由微粒诱导的骨溶解。为防治人工关节置换后假体松动提供了一种很有应用前景的治疗策略。

关键词(KeyWords)： 反义核酸;骨溶解;松动;关节置换;TNF-α

Abstract:

Keywords:

基金项目(Foundation): 江苏省自然科学基金(No.BK2005085);; 军队“十一五”计划项目(No.06G043)

作者(Author): 王瑞;郭亭;曾晓峰;周利武;董磊;张峻峰;赵建宁;

Email:

DOI:

参考文献(References)：

• [1]Knocha M,Wedemeyera C,Pingsmanna A,et al.The decrease of par-ticle-induced osteolysis after a single dose of bisphosphonate[J].Bio-materials,2005,26:1803-1808.
• [2]Kotake S,Udagawa N,Takahashi N,et al.IL-17 in synovial fluidsfrom patients with rheumatoid arthritis is a potent stimulator of oste-oclastogenesis[J].J Clin Invest,1999,9:1345-1352.
• [3]Sabokbar A,Fujikawa Y,Neale S,et al.Human arthroplasty derivedmacrophages differentiate into osteoclastic bone resorbing cells[J].Ann Rheum Dis,1997,7:414-420.
• [4]张超,戴尅戎,汤亭亭,等.红霉素抑制磨损颗粒诱发体内骨溶解的研究[J].中国矫形外科杂志,2007,15:1100-1103.
• [5]Rena WP,Markela DC,Zhang R,et al.Association between UHM-WPE particle-induced inflammatory osteoclastogenesis and expressionof RANKL,VEGF,and Flt-1 in vivo[J].Biomaterials,2006,27:5161-5169.
• [6]Desai SB,Furst DE.Problems encountered during anti-tumour necro-sis factor therapy[J].Best Pract Res Clen,2006,20:757-790.
• [7]Rice R,Rice DPC,Olsen BR,et al.Progression of calvarial bone de-velopment requires Foxc1 regulation of Msx2 and Alx4[J].Dev Biol,2003,262:75-87.
• [8]Boyce BF,Li P,Yao Z,et al.TNF-αand pathologic bone resorption[J].Keio J Med,2005,54:127-131.
• [9]Feldmann M.Development of anti-TNF therapy for rheumatoid arthri-tis[J].Nat Rev Immuno,2002,2:364-371.
• [10]Taylor PC.Anti-TNF-αtherapy for rheumatoid arthritis:an update[J].Intern Med,2003,42:15-20.
• [11]Palladino MA,Bahjat FR,Theodorakis EA,et al.Anti-TNF-αthera-pies:the next generation[J].Nat Rev Drug Disc,2003,2:736-746.
• [12]Schwarz EM,Benz EB,Lu AP,et al.Quantitative small-animal surro-gate to evaluate drug efficacy in preventing wear debris-induced oste-olysis[J].J Orthop Res,2000,18:849-855.
• [13]Opalinska JB,Gewirtz AM.Nucleic-acid therapeutics:basic principlesand recent applications[J].Nat Rev Drug Discov,2002,1:503-514.
• [14]Sullenger BA,Gilboa E.Emerging clinical applications of RNA[J].Nature,2002,418:252-258.
• [15]Anderson KP,FoxMC,Brown-Driver V,et al.Inhibition of human cy-tomegalovirus immediate-early gene expression by an antisense oligo-nucleotide complementary to immediate-early RNA,antimicrob[J].Agents Chemother,1996,40:2004-2011.
• [16]Qiu S,Adema CM,Lane T.A computational study of offtarget effectsof RNA interference[J].Nucleic Acids Res,2005,33:1834-1847.
• [17]Aboul-Fadl T.Antisense oligonucleotides:the state of the art[J].Curr Med Chem,2005,12:2193-2214.